The Department of Health and Human Services (HHS) on Tuesday announced it was awarding a nearly $20 million contract to AmerisourceBergen to expand the distributions of treatments and vaccines to treat the ongoing monkeypox outbreak. The $19.8 million contract to AmerisourceBergen, one of the largest drug distribution companies in the U.S., will allow for the…
The U.S. Department of Health and Human Services ((HHS)) on Tuesday said it had awarded a $19.8M contract to drug distributor AmerisourceBergen (ABC) to expand and speed up the…
NEW YORK — The U.S. Department of Health and Human Services (HHS) on Tuesday said it will significantly expand the number of distribution locations for monkeypox vaccines and treatments through a new $20 million contract with AmerisourceBergen Corp. Under the new contract, HHS said it will be able to make up to 2,500 shipments per […]
Federal Government To Stop Paying For COVID Shots, Tests, & Treatments The Biden administration is starting to transition the federal government away from paying for Covid-19 vaccines, tests and treatments, with the shift likely to materialize this fall. "One of the things we''ve spent a lot of time thinking about in the last many months…is getting us out of that acute emergency phase where the US government is buying the vaccines, buying the treatments, buying the diagnostic tests," White House Covid-19 Response Coordinator Ashish Jha said at a US Chamber of Commerce Foundation event on Tuesday. "My hope is that in 2023, you''re going to see the commercialization of almost all of these products," Jha added. "Some of that is actually going to begin this fall, in the days and weeks ahead." Earlier this year, a White House request for another $10 billion in pandemic response funding stalled in Congress. On Thursday, The Wall Street Journal reported that, on Aug. 30, the Department of Health and Human Services (HHS) will host a meeting of pharmaceutical companies, state health departments and pharmacies to start sorting out how to make the transition, which also include regulatory adjustments.
Company Will Optimize Centers for Medicare & Medicaid Services'' Platforms to Improve Operations and End-user Experience FAIRFAX, Va. , Aug. 2, 2022 /PRNewswire/ -- The U.S. Department of Health and Human Services'' Centers for Medicare & Medicaid Services (CMS) recently selected global consulting and digital services provider ICF (NASDAQ: ICFI ) for a $33 million recompete contract to provide digital modernization services to its Office of Information Technology. The contract has a term of four years, including a one-year base and three one-year options. ICF will bring its extensive experience modernizing business services using ServiceNow to help CMS enhance mission delivery through greater operational efficiencies, increased … Full story available on Benzinga.com
New data from HHS shows that around 2.8M doses of Pfizer''s COVID-19 antiviral Paxlovid were administered from Dec. 17, 2021-July 17, 2022.
The stock market in 2022 has been volatile, and stocks are now officially in a bear market — which could be good news for long-term investors. Finding the best long-term stocks is about digging through stable companies with solid financial and business performance over time. These stocks may be volatile, as a broader stock market selloff will probably send them lower as well. It is impossible to entirely predict the actual bottom for any stock price. But picking companies with momentum in earnings and revenue that are trading at cheap valuations makes stock investing a long-term success. It takes a lot of patience and determination to find the best long-term stocks, but statistics show it is one of the wisest moves. Short-term investing is not suitable for everyone, as the wild price swings can not only make you nervous but also force you to make trades that will harm your portfolio. 7 Best Small-Cap Growth Stocks to Buy Now With all that said, here are some of the best long-term stocks that should perform well over the coming years.
President Joe Biden speaks about abortion access during an event in the Roosevelt Room of the White House, Friday, July 8, 2022, in Washington. Evan Vucci/AP WASHINGTON — President Joe Biden delivered impassioned remarks Friday condemning the “extreme” Supreme Court majority that ended a constitutional right to abortion and pleading with Americans upset by the decision to “vote, vote, vote vote” in November. He signed an executive order to try to protect access to the procedure under mounting pressure from fellow Democrats to be more forceful in response to the ruling. The actions Biden outlined are intended to mitigate some potential penalties that women seeking abortion may face after the ruling, but his order cannot restore access to abortion in the more than a dozen states where strict limits or total bans have gone into effect. About a dozen more states are set to impose additional restrictions. Biden acknowledged the limitations facing his office, saying it would require an act of Congress to restore nationwide access to the way it was before the June 24 decision. “The fastest way to restore Roe is to pass a national law,” Biden said. “The challenge is go out and vote.
Adm. Brett Giroir pushed back on some of the public health recommendations made by his colleague on the White House Coronavirus Task Force, Dr. Anthony Fauci.
Steps like closing bars and wearing masks could have the same impact as widespread economic shutdowns, Admiral Brett Giroir said Sunday.
Email from HHS adviser accusing CDC of ‘undermining President’ offers window into pressure on nation’s public health agency.
President Trump repeatedly hyped an obscure antimalarial drug, hydroxychloroquine, as a potential miracle cure for COVID-19. But there was almost no solid scientific evidence to back that claim, and researchers quickly established that it had no effect on the disease. Despite its unlikely profile as a cure, hydroxychloroquine has received more federal research funding than any other single potential treatment, an Insider investigation has found. Taxpayers have devoted at least $88 million — and likely much more — on research and prescriptions for the drug. "It's been a disaster," Arthur Caplan, the founder of New York University School of Medicine's division of medical ethics, said. "There's too much money … chasing around that drug based on very weak evidence in the literature and a presidential endorsement." Visit Business Insider's homepage for more stories . Most Americans had never heard of hydroxychloroquine — the obscure antimalarial drug discovered in 1945 — until March 19. That's when President Donald Trump, speaking at a Coronavirus Task Force press conference in the White House briefing room with the blustering confidence of an old-time snake-oil salesman, first touted it as a likely miracle cure to defeat COVID-19.
The U.S. Department of Health and Human Services (HHS) said on Tuesday there would be temporary free COVID-19 testing in three cities in Florida, Louisiana and Texas as the U.S. states tackle surging cases and hospitalizations.
WASHINGTON, July 7, 2020 /PRNewswire/ -- The expertise of the U.S. Centers for Disease Control and Prevention (CDC) and all public health agencies is critical to protecting Americans' health during the COVID-19 crisis, said a letter to Health and Human Services Secretary Alex Azar from…
Sen. Elizabeth Warren is raising concerns over an effort to track coronavirus spread that involves tech company Palantir.
The US Department for Health and Human Services (HHS) announced on July 1 that it will be buying up virtually the entire stock of Gilead’s remdesivir drug, which has been found to be effectiv…
The US Department of Health and Human Services (HHS) was able to secure 100 per cent of Gilead Sciences’ projected production of remdesivir for July, and 90 per cent of its production for August and September.
Amid record unemployment, HHS is doling out more than $1 billion in coronavirus contracts that omit price-gouging safeguards. The post The Trump Administration Is Waiving the Public’s Right to Affordable Coronavirus Treatments appeared first on The Intercept .
The US has struck a deal with Gilead Sciences to purchase more than 90% of the global supply of remdesivir. Remdesivir has been shown to help moderately ill patients recover more quickly from COVID-19, and is only of the only treatments that has been found to be as effective. HHS secretary Alex Azar called it an "amazing deal," but it leaves many countries with few options. The treatment, which was previously donated by Gilead, has now been priced at $2,340 per course for developed nations, including the US. Visit Business Insider's homepage for more stories . The US has purchased more than 90% of the world's supply of remdesivir, the only proven treatment for COVID-19, which will leave little for the rest of the world for at least the next three months. Gilead Sciences, the US-based company that makes the drug, agreed to sell more than 500,000 treatment courses to the US until September, which is almost the entire amount it has the ability to produce. Remdesivir, which was originally developed to treat Ebola, has been shown to help moderately ill patients recover more quickly from COVID-19, and was granted temporary FDA approval for that purpose in early May.
That means that the cost of a five-day treatment course in the U.S. and other developed countries will jump to $3,120.
The price for U.S. private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir. Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS), with the agency and states
Azar also denied that states reopening prematurely was tied to the spike in coronavirus cases and instead blamed "inappropriate individual behavior" that has spread the virus.
HHS ecretary Alex Azar defended Trump's decision to not wear a face covering in public on Sunday, saying the president is tested for the coronavirus on a daily basis so wearing a mask isn't necessary.
The secretary of Health and Human Services said Sunday the “window is closing” to curb the surge of coronavirus cases — and encouraged all Americans to follow the government’s guidelines about social distancing and mask wearing. “So we’ve got the tools to do this … but the window is closing. We have to act, and…
Health and Human Services Secretary Alex Azar warned that the United States is running out of time to combat the spread of the coronavirus as the country sees cases spiking in some regions.
The HHS secretary also called for shifting the country's Covid-19 testing strategy to broadly test pools of people in high risk populations.
The Health and Human Services Secretary said "individuals need to act responsibly" to slow the spread, including social distancing and "face coverings."
Rick Bright claims the HHS secretary instructed staffers not to cooperate with him in his new role.
Health and Human Services Secretary Alex Azar said Thursday he does not foresee states needing to implement new stay-at-home orders despite the surge in new coronavirus cases across the country.
HHS Secretary Alex Azar says we can get back to work and school if we act responsibly
Health and Human Services Secretary Alex Azar weighs in on the surge of coronavirus cases on ‘America’s Newsroom.’
Alex Azar, HHS Secretary, discusses why coronavirus cases are on the rise and the virus is spreading
Officials quickly organized a press call to explain it was the plan all along.
Michael Caputo, a longtime Trump loyalist and friend of Roger Stone, raged at reporters over articles about federal funding of coronavirus testing sites.
President Trump signed an executive order directing the Health and Human Services Department to further assist foster children with what the department says are bipartisan measures particularly needed during the coroanvirus pandemic.
Admiral Brett Giroir, HHS Assistant Secretary, testifies the nation has performed over 27 million coronavirus tests, averaging 500,00 tests per day
White House and Trump campaign staff members dismissed the remarks as humor.
Senate Democrats are asking the Health and Human Services Department watchdog to investigate President Donald Trump's recent assertion that he asked his staff to "slow the testing down" for coronavirus.
WASHINGTON, June 22, 2020 /PRNewswire/ -- Today, Dialysis Patient Citizens (DPC) filed suit in the United States District Court for the District of Columbia against Health and Human Services Secretary Alex Azar, Centers for Medicare and Medicaid Services Administrator Seema Verma, the U.S….
‘Now members [of Congress] are contacting HHS with their individual priorities and complaining the dollars are not spent to their wishes,’ said HHS spokesman Michael Caputo.
Now that the US Food and Drug Administration (FDA) has revoked permission for hydroxychloroquine to be used for the treatment of COVID-19, the federal government is left with a stockpile of 63 million doses, according to an HHS spokesperson.
This story was delivered to Insider Intelligence Digital Health Briefing subscribers earlier this morning. Insider Intelligence publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. You can learn more about subscribing here. EHR giant Epic and Health Care Services Corporation (HCSC) — an independent licensee of five Blue Cross Blue Shield (BCBS) plans — introduced a "two-way" information exchange platform between the entities. The system will enable efficient exchange of data and insights between BCBS payers, patients, and in-network providers — and aims to provide a more holistic view of patient data. Interoperability challenges have plagued health systems for years — and we think the HCSC-Epic platform could begin to resolve some of these issues: Admin tasks are a key driver of physician burnout — and the new platform can relieve physicians of some admin-related stress by streamlining review of EHR patient data and mitigating time spent in EHRs.
HHS is trying to get them funds, but the process has been confusing.
The US now has 66 million excess anti-malaria pills after the FDA U-turned on chloroquine and hydroxychloroquine. The FDA said the drugs were likely ineffective in treating COVID-19, and could be dangerous. It previously allowed the drugs to be used in hospitalized coronavirus patients. The government has sent out 31 million hydroxychloroquine tablets to state agencies, The New York Times reported , and now has 63 million left over, alongside 3 million chloroquine pills. Officials are now trying to figure out what to do with the excess drugs, and are working to "determine to available options," the Department of Health and Human Services said. Dr. Rick Bright, the former head of the US Biomedical Advanced Research and Development Authority (BARDA), said they "should be destroyed." Visit Business Insider's homepage for more stories . The US is sitting on a pile of 66 million anti-malaria pills after they were scrapped as a treatment for COVID-19 by the Food and Drug Administration (FDA).
Donald Trump's administration has rolled back nondiscrimination healthcare protections for women and transgender people by reversing a rule that would prevent healthcare workers and insurance companies that receive federal funds from refusing to provide services like abortion or gender-affirming care. The changes arrive in the middle of Pride month on the anniversary of the
CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) continues to expand COVID-19 testing sites with 21 additional drive-through locations opening Thursday, June 11, 2020, through its partnership with the U.S. Department of Health and Human Services (HHS). Similar to Rite Aid’s existing testing sites, the new locations will utilize self-swab nasal tests overseen by Rite Aid pharmacists, and will operate Monday through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5 p.m. Rite Aid’s
The leaders of the Senate Finance Committee are urging a watchdog for the Department of Health and Human Services (HHS) to issue alerts in an effort to protect residents of nursing homes and assisted living facilities from having their coronavirus…
The only effective coronavirus treatment approved for standard care so far will run out at the end of this month, the US government said. Our supply of remdesivir is expected to be depleted by June 29th, and Gilead likely won't be able to deliver more until this summer, as manufacturing efforts increase. Gilead plans to have more than 500,000 treatment courses by October, and more than 1 million by December. The race to develop vaccines and new drugs for the novel coronavirus is promising, but it'll be months before they could be ready. Once they're approved, there will be a limited supply at first and it might take a few more months for the drugs to be widely available. Separately, doctors have obtained good results at repurposing some of the existing drugs to treat COVID-19 patients, with several clinical trials aimed at offering new treatment protocols for the disease. But only one of them was officially confirmed to be effective in certain types of COVID-19 cases. That's remdesivir , the drug that Gilead Sciences developed for Ebola.
The US government will run out of remdesivir drugs at the end of June, and does not know when it will get more. The Department of Health and Human Services told CNN that Gilead, which makes the drug, will ship a final batch on the week of June 29. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Dr. Robert Kadlec told the network. Remdesivir is the only widely-approved COVID-19 treatment, and early studies show it helps mitigate the effect of the virus. All 1.5 million vials of remdesivir that Gilead has in stock are currently in circulation. Gilead says it will get new stocks of crucial raw materials in July, which mean they can make more. Visit Business Insider's homepage for more stories . The US supply of the COVID-19 treatment remdesivir will run out at the end of June, the Department of Health and Human Services has said. Dr. Robert Kadlec, a HHS official, told CNN that Gilead Sciences , which created the drug, will send the government a final shipment the week of June 29, but after that, the HHS does not know when it will get more. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said.
CHARLOTTE, N.C.--(BUSINESS WIRE)--Premier Inc. (NASDAQ: PINC) today provided the U.S. Department of Health and Human Services (HHS) and Congress with a list of 24 regulatory waivers that should be made permanent as the COVID-19 pandemic subsides. The temporary waivers were granted earlier in the year to streamline care delivery and prevent the spread of infection. “During the height of the COVID-19 pandemic, waivers cleared away cumbersome barriers and allowed health systems to save lives in th
- ← Previous
- 1
- 2
- 3
- 4
- 5
- Next →